# OnCo record ros1-positive-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ros1-positive-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ros1-positive-nsclc" ;
  schema:name "ROS1-positive non-small-cell lung cancer"@en ;
  schema:alternateName "ROS1-rearranged lung cancer"@en, "ROS1 fusion NSCLC"@en, "CD74-ROS1 lung cancer"@en ;
  schema:description "ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."@en ;
  schema:url <https://onco.cc/cancers/ros1-positive-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/ROS1> ;
  schema:citation <https://en.wikipedia.org/wiki/ROS1>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/taletrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/zidesamtinib/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/nuvation-bio/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/nuvalent/> ;
  onco:pathways <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/tki-term/> ;
  onco:trials <https://onco.cc/trials/nct03093116/>, <https://onco.cc/trials/nct04395677/>, <https://onco.cc/trials/nct02568267/> ;
  onco:people <https://onco.cc/people/alexander-drilon/>, <https://onco.cc/people/ross-camidge/>, <https://onco.cc/people/cho-byoung-chul/> ;
  onco:pipeline <https://onco.cc/drugs/zidesamtinib/>, <https://onco.cc/drugs/taletrectinib/>, <https://onco.cc/trials/nct04395677/> ;
  onco:standardOfCare <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/trials/nct03093116/>, <https://onco.cc/drugs/taletrectinib/>, <https://onco.cc/trials/nct04395677/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/trials/nct02568267/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/taletrectinib/>, <https://onco.cc/drugs/zidesamtinib/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/terms/brain-metastases/> .